1
|
Accumulation of zoledronic acid in rabbit intervertebral discs. J Chromatogr B Analyt Technol Biomed Life Sci 2022; 1197:123229. [DOI: 10.1016/j.jchromb.2022.123229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 03/01/2022] [Accepted: 03/15/2022] [Indexed: 11/19/2022]
|
2
|
Calcium Phosphate Ceramics Can Prevent Bisphosphonate-Related Osteonecrosis of the Jaw. MATERIALS 2020; 13:ma13081955. [PMID: 32331240 PMCID: PMC7215435 DOI: 10.3390/ma13081955] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 04/13/2020] [Accepted: 04/20/2020] [Indexed: 12/20/2022]
Abstract
Bisphosphonate-associated osteonecrosis of the jaw (BRONJ), a post-surgical non-healing wound condition, is one of the most common side effects in patients treated with nitrogen-containing bisphosphonates. Its physiopathology has been related with suppression of bone turnover, of soft tissue healing and infection. Biphasic calcium phosphates (BCP) are used as a drug delivery vehicle and as a bone substitute in surgical wounds. Due to their capacity to adsorb zoledronate, it was hypothesized these compounds might have a protective effect on the soft tissues in BRONJ wounds. To address this hypothesis, a reproducible in vivo model of BRONJ in Wistar rats was used. This model directly relates chronic bisphosphonate administration with the development of osteonecrosis of the jaw after tooth extraction. BCP granules were placed in the alveolus immediately after tooth extraction in the test group. The animals were evaluated through nuclear medicine, radiology, macroscopic observation, and histologic analysis. Encouragingly, calcium phosphate ceramics were able to limit zoledronate toxicity in vivo and to favor healing, which was evidenced by medical imaging (nuclear medicine and radiology), macroscopically, and through histology. The studied therapeutic option presented itself as a potential solution to prevent the development of maxillary osteonecrosis.
Collapse
|
3
|
Gundogdu E, Demir ES, Özgenç E, Yeğen G, Aksu B. Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate. ACS OMEGA 2020; 5:5297-5305. [PMID: 32201818 PMCID: PMC7081423 DOI: 10.1021/acsomega.9b04327] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 02/20/2020] [Indexed: 05/10/2023]
Abstract
The clinical impact and accessibility of 99mTc tracers for cancer diagnosis would be greatly enhanced by the availability of a new, simple, and easy labeling process and radiopharmaceuticals. In this study, Technetium-99m-imatinib mesylate ([99mTc]TcIMT) was developed and prepared as a new radiopharmaceutical for breast cancer diagnosis. The effect of critical process parameters on the product quality and stability of [99mTc]TcIMT was investigated using the quality by design concept of the ICH Q8 (Pharmaceutical Development) guideline. [99mTc]TcIMT was subjected to in vitro cell binding studies to determine healthy and cancer cell affinity using HaCaT and MCF-7 cells, respectively. The optimal radiolabeling procedure with 1 mg of IMT, 500 μg of stannous chloride, 0.1 mg of ascorbic acid, and 1mCi 99mTc radioactivity was obtained for [99mTc]TcIMT. The pH of the reaction mixture was adjusted to 10 and allowed to react for 15 min at room temperature. The radiochemical purity of [99mTc]TcIMT was found to be higher than 90% at room temperature up to 6 h. Chromatography analysis revealed >85% [99mTc]TcIMT complex formation with promising stability in saline, cell medium, and serum up to 6 h. The radiolabeled complex showed a higher cell-binding ratio to MCF-7 cells (88.90% ± 3.12) than HaCaT cells (45.64 ± 4.72) when compared to 99mTc. Our findings show that the developed preparation method for [99mTc]TcIMT falls well within the proven acceptable ranges. Applying quality by design (QbD) principles is feasible and worthwhile for the preparation of [99mTc]TcIMT. In conclusion, radiochemical purity, stability, and in vitro cell binding evaluation of the [99mTc]TcIMT complex indicate that the agent can be utilized for imaging of breast cancer cells.
Collapse
Affiliation(s)
- Evren Gundogdu
- Department
of Radiopharmacy, Faculty of Pharmacy, Ege
University, Bornova 35040, Izmir, Turkey
- E-mail: . Phone: 00902323112210. Fax: 00902323885258
| | - Emine Selin Demir
- Department
of Radiopharmacy, Faculty of Pharmacy, Ege
University, Bornova 35040, Izmir, Turkey
| | - Emre Özgenç
- Department
of Radiopharmacy, Faculty of Pharmacy, Ege
University, Bornova 35040, Izmir, Turkey
| | - Gizem Yeğen
- Department
of Pharmaceutical Technology, Faculty of Pharmacy, Altinbas University, Esentepe 34217, Istanbul, Turkey
| | - Buket Aksu
- Department
of Pharmaceutical Technology, Faculty of Pharmacy, Altinbas University, Esentepe 34217, Istanbul, Turkey
| |
Collapse
|
4
|
Salek N, Mehrabi M, Shirvani Arani S, Bahrami Samani A, Erfani M, Vosoghi S, Ghannadi Maragheh M, Shamsaei M. Production, quality control, and determination of human absorbed dose of no carrier added177Lu-risedronate for bone pain palliation therapy. J Labelled Comp Radiopharm 2016; 60:20-29. [DOI: 10.1002/jlcr.3466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Revised: 08/14/2016] [Accepted: 09/08/2016] [Indexed: 11/08/2022]
Affiliation(s)
- Nafise Salek
- Nuclear Fuel Cycle Research School; Nuclear Science and Technology Research Institute; Tehran Iran
- Faculty of Energy Engineering and Physics; Amirkabir University of Technology; Tehran Iran
| | - Mohsen Mehrabi
- Faculty of Energy Engineering and Physics; Amirkabir University of Technology; Tehran Iran
| | | | - Ali Bahrami Samani
- Nuclear Fuel Cycle Research School; Nuclear Science and Technology Research Institute; Tehran Iran
| | - Mostafa Erfani
- Nuclear Fuel Cycle Research School; Nuclear Science and Technology Research Institute; Tehran Iran
| | - Sara Vosoghi
- Nuclear Fuel Cycle Research School; Nuclear Science and Technology Research Institute; Tehran Iran
| | | | - Mojtaba Shamsaei
- Faculty of Energy Engineering and Physics; Amirkabir University of Technology; Tehran Iran
| |
Collapse
|
5
|
Akbar MU, Bokhari TH, Roohi S, Zia KM, Zuber M, Parveen N, Ali N. Development, optimization, and biovalidation of 99mTc–insulin complex. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2016. [DOI: 10.1134/s1068162016050125] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
6
|
Qiu L, Lv G, Guo L, Chen L, Luo S, Zou M, Lin J. Synthesis, crystal structure and antitumor effect of a novel copper(II) complex bearing zoledronic acid derivative. Eur J Med Chem 2014; 89:42-50. [PMID: 25462224 DOI: 10.1016/j.ejmech.2014.10.028] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 10/08/2014] [Accepted: 10/12/2014] [Indexed: 12/29/2022]
Abstract
A great majority of Cu(II) complexes currently studied in the anticancer research field exert their antiproliferative activities through ligand exchange. In this work, we present the synthesis and structural characterization of two novel Cu(II) complexes, {[Cu3(ZL)2(H2O)6]·6H2O}n (1) (ZL = 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid) and [Cu(IPrDP)2]·3H2O (2) (IPrDP = 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diyldiphosphonic acid). Due to the insolubility of polymer 1 in common solvents, only the biological activities of complex 2 were investigated. The antitumor activity of complex 2 was evaluated against a panel of human cancer cell lines, including U2OS, A549, HCT116, MDA-MB-231 and HepG2. Complex 2 exhibited comparable cytotoxic effect to cisplatin (CDDP) against the human colon carcinoma cells HCT116, and superior selectivity for inhibiting human hepatocarcinoma cells rather than normal liver cells. The cell cycle distribution analysis indicates that complex 2 inhibits human carcinoma cells by inducing the cell cycle arrest at the G2/M phase, showing a similar mechanism of action to that of CDDP. The binding interaction of complex 2 with calf thymus DNA (CT-DNA) has been explored by UV-vis absorption and circular dichroism (CD), demonstrating complex 2 has a moderate binding affinity for DNA through intercalation.
Collapse
Affiliation(s)
- Ling Qiu
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Gaochao Lv
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Liubin Guo
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Liping Chen
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Shineng Luo
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Meifen Zou
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
| | - Jianguo Lin
- Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China.
| |
Collapse
|
7
|
Petriev VM, Tishchenko VK, Siruk OV, Smoryzanova OA, Skvortsov VG. Pharmacokinetic Study of the New Diagnostic Radiopharmaceutical 99mTc-Pentaphosphonic Acid in Rats with an Experimental Bone-Fracture Model. Pharm Chem J 2014. [DOI: 10.1007/s11094-014-1110-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Pharmacokinetics of 188Re-labeled pentaphosphonic acid in rats with experimental bone callosity. Pharm Chem J 2013. [DOI: 10.1007/s11094-013-0939-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Choi M, Shin DH, Kim JS. Repositioning of zoledronic acid for breast cancer using transferrin-conjugated liposome. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2013. [DOI: 10.1007/s40005-013-0091-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
10
|
Qiu L, Lin JG, Gong XD, Cheng W, Luo SN. Substituent Effect on the Structure and Biological Property of99mTc-Labeled Diphosphonates: Theoretical Studies. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.12.4084] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Ortega AJ“AJ, Campbell PM, Hinton R, Naidu A, Buschang PH. Local application of zoledronate for maximum anchorage during space closure. Am J Orthod Dentofacial Orthop 2012. [DOI: 10.1016/j.ajodo.2012.07.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Preparation and in vivo biological investigation of 99mTc-HEIDP as a novel radioligand for bone scanning. J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.2941] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
13
|
Qiu L, Lin J, Luo S, Wang Y, Cheng W, Zhang S. A novel 99mTc-labeled dimethyl-substituted zoledronic acid (DMIDP) with improved bone imaging efficiency. RADIOCHIM ACTA 2012. [DOI: 10.1524/ract.2012.1934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
A novel zoledronic acid (ZL) derivative, 1-hydroxy-2-(2,4-dimethyl-1H-imidazol-1-yl)-ethane-1,1-diyldiphosphonic acid (DMIDP, dimezoledronate), was successfully prepared and labeled with 99mTc in a high labeling yield. The biodistribution in mice shows that 99mTc-DMIDP has significant advantage regarding bone resorption and clearance from soft tissues compared with 99mTc-ZL and the clinically widely-used bone-imaging agent 99mTc-MDP (methylenediphosphonic acid). Kinetics of blood clearance displayed that distribution half-life (T
1/2α
) and elimination half-life (T
1/2β
) of 99mTc-DMIDP were 2.53 min and 23.53 min, while those of 99mTc-ZL were 2.28 and 52.63 min, respectively. Excellent images of the rabbit skeleton can be quickly obtained from 99mTc-DMIDP, which was faster than 99mTc-ZL and 99mTc-MDP. The present findings indicate that 99mTc-DMIDP possesses excellent potential for application as a novel bone scanning agent.
Collapse
Affiliation(s)
- Ling Qiu
- Jiangsu Institute of Nuclear Medicine, Ministry of Health, Wuxi 214063, Volksrepublik China
| | | | - Shineng Luo
- Jiangsu Institute of Nuclear Medicine, Ministry of Health, Wuxi 214063, Volksrepublik China
| | - Yan Wang
- Jiangsu Institute of Nuclear Medicine, Ministry of Health, Wuxi 214063, Volksrepublik China
| | - Wen Cheng
- Jiangsu Institute of Nuclear Medicine, Ministry of Health, Wuxi 214063, Volksrepublik China
| | - Shu Zhang
- Jiangsu Institute of Nuclear Medicine, Ministry of Health, Wuxi 214063, Volksrepublik China
| |
Collapse
|
14
|
Lin J, Qiu L, Cheng W, Luo S, Xue L, Zhang S. Development of superior bone scintigraphic agent from a series of 99mTc-labeled zoledronic acid derivatives. Appl Radiat Isot 2012; 70:848-55. [DOI: 10.1016/j.apradiso.2011.12.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2011] [Revised: 11/30/2011] [Accepted: 12/08/2011] [Indexed: 10/28/2022]
|
15
|
Wang Y, Luo S, Lin J, Qiu L, Cheng W, Zhai H, Nan B, Ye W, Xia Y. Animal studies of 99mTc–i-PIDP: A new bone imaging agent. Appl Radiat Isot 2011; 69:1169-75. [DOI: 10.1016/j.apradiso.2011.03.045] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2010] [Revised: 03/04/2011] [Accepted: 03/30/2011] [Indexed: 10/18/2022]
|
16
|
Qiu L, Lin JG, Gong XD, Ju XH, Luo SN. Theoretical Studies on Electronic Structure and Absorption Spectrum of Prototypical Technetium-Diphosphonate Complex99mTc-MDP. B KOREAN CHEM SOC 2011. [DOI: 10.5012/bkcs.2011.32.7.2358] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Lin J, Qiu L, Cheng W, Luo S, Ye W. Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. Nucl Med Biol 2011; 38:619-29. [DOI: 10.1016/j.nucmedbio.2010.12.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Revised: 11/10/2010] [Accepted: 12/07/2010] [Indexed: 10/18/2022]
|
18
|
Preparation and preclinical pharmacological study on a novel bone imaging agent 99mTc-EMIDP. Appl Radiat Isot 2010; 68:1616-22. [DOI: 10.1016/j.apradiso.2010.03.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2009] [Revised: 03/01/2010] [Accepted: 03/03/2010] [Indexed: 11/18/2022]
|